Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Payne

Showing results (441-450 of 459) with videos related to

Pageof 46
Sort By:
MMWR. Morbidity and Mortality Weekly Report|May 25, 2023
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023Ruth Link-Gelles, Zachary A Weber, Sarah E Reese, et al.
MMWR. Morbidity and Mortality Weekly Report|March 28, 2024
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024Ruth Link-Gelles, Elizabeth A K Rowley, Malini B DeSilva, et al.
Lancet Regional Health. Americas|October 3, 2025
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysisAmanda B Payne, Steph Battan-Wraith, Elizabeth A K Rowley, et al.
JAMA Network Open|June 25, 2025
Estimated 2023-2024 COVID-19 Vaccine Effectiveness in AdultsRuth Link-Gelles, Elizabeth A K Rowley, Stephanie A Irving, et al.
Lancet (London, England)|October 19, 2024
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysisAmanda B Payne, Janet A Watts, Patrick K Mitchell, et al.
JAMA Internal Medicine|June 15, 2026
Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in AdultsRyan E Wiegand, Amanda B Payne, Josephine Mak, et al.
Vaccine|July 2, 2026
Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024Amber Kautz, Duck-Hye Yang, Sean Chickery, et al.
MMWR. Morbidity and Mortality Weekly Report|December 5, 2025
Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025Laura D Zambrano, Regina M Simeone, Margaret M Newhams, et al.
Vaccine|July 15, 2025
Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive ageEmily L Reeves, Kristin Dascomb, Stephanie A Irving, et al.
MMWR. Morbidity and Mortality Weekly Report|March 12, 2026
Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026Patrick Maloney, Emily L Reeves, Kristina Wielgosz, et al.
Pageof 46

Showing results (441-450 of 459) with videos related to

Sort By:
Pageof 46
MMWR. Morbidity and Mortality Weekly Report|May 25, 2023
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023Ruth Link-Gelles, Zachary A Weber, Sarah E Reese, et al.
MMWR. Morbidity and Mortality Weekly Report|March 28, 2024
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024Ruth Link-Gelles, Elizabeth A K Rowley, Malini B DeSilva, et al.
Lancet Regional Health. Americas|October 3, 2025
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysisAmanda B Payne, Steph Battan-Wraith, Elizabeth A K Rowley, et al.
JAMA Network Open|June 25, 2025
Estimated 2023-2024 COVID-19 Vaccine Effectiveness in AdultsRuth Link-Gelles, Elizabeth A K Rowley, Stephanie A Irving, et al.
Lancet (London, England)|October 19, 2024
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysisAmanda B Payne, Janet A Watts, Patrick K Mitchell, et al.
JAMA Internal Medicine|June 15, 2026
Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in AdultsRyan E Wiegand, Amanda B Payne, Josephine Mak, et al.
Vaccine|July 2, 2026
Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024Amber Kautz, Duck-Hye Yang, Sean Chickery, et al.
MMWR. Morbidity and Mortality Weekly Report|December 5, 2025
Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025Laura D Zambrano, Regina M Simeone, Margaret M Newhams, et al.
Vaccine|July 15, 2025
Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive ageEmily L Reeves, Kristin Dascomb, Stephanie A Irving, et al.
MMWR. Morbidity and Mortality Weekly Report|March 12, 2026
Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026Patrick Maloney, Emily L Reeves, Kristina Wielgosz, et al.
Pageof 46